These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 39085255)

  • 1. A tumor targeted nano micelle carrying astragaloside IV for combination treatment of bladder cancer.
    Kong C; Sun J; Hu X; Li G; Wu S
    Sci Rep; 2024 Jul; 14(1):17704. PubMed ID: 39085255
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tumor acidity-activatable macromolecule autophagy inhibitor and immune checkpoint blockade for robust treatment of prostate cancer.
    Wang Y; Lei H; Yan B; Zhang S; Xu B; Lin M; Shuai X; Huang J; Pang J
    Acta Biomater; 2023 Sep; 168():593-605. PubMed ID: 37474083
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CD122-directed interleukin-2 treatment mechanisms in bladder cancer differ from αPD-L1 and include tissue-selective γδ T cell activation.
    Reyes RM; Deng Y; Zhang D; Ji N; Mukherjee N; Wheeler K; Gupta HB; Padron AS; Kancharla A; Zhang C; Garcia M; Kornepati AVR; Boyman O; Conejo-Garcia JR; Svatek RS; Curiel TJ
    J Immunother Cancer; 2021 Apr; 9(4):. PubMed ID: 33849925
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Functionalized biomimetic nanoparticles combining programmed death-1/programmed death-ligand 1 blockade with photothermal ablation for enhanced colorectal cancer immunotherapy.
    Xiao Y; Zhu T; Zeng Q; Tan Q; Jiang G; Huang X
    Acta Biomater; 2023 Feb; 157():451-466. PubMed ID: 36442821
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Multifunctional targeting micelle nanocarriers with both imaging and therapeutic potential for bladder cancer.
    Lin TY; Zhang H; Luo J; Li Y; Gao T; Lara PN; de Vere White R; Lam KS; Pan CX
    Int J Nanomedicine; 2012; 7():2793-804. PubMed ID: 22745542
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Astragaloside IV Exerts Anti-tumor Effect on Murine Colorectal Cancer by Re-educating Tumor-Associated Macrophage.
    Liu F; Ran F; He H; Chen L
    Arch Immunol Ther Exp (Warsz); 2020 Oct; 68(6):33. PubMed ID: 33095374
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A dual-functional oncolytic adenovirus ZD55-aPD-L1 scFv armed with PD-L1 inhibitor potentiates its antitumor activity.
    Mei S; Peng S; Vong EG; Zhan J
    Int Immunopharmacol; 2024 Feb; 128():111579. PubMed ID: 38278066
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nanoparticle-integrated dissolving microneedles for the co-delivery of R848/aPD-1 to synergistically reverse the immunosuppressive microenvironment of triple-negative breast cancer.
    Huang S; Wen T; Wang J; Wei H; Xiao Z; Li B; Shuai X
    Acta Biomater; 2024 Mar; 176():344-355. PubMed ID: 38244662
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Local and Targeted Delivery of Immune Checkpoint Blockade Therapeutics.
    Han X; Li H; Zhou D; Chen Z; Gu Z
    Acc Chem Res; 2020 Nov; 53(11):2521-2533. PubMed ID: 33073988
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Precision USPIO-PEG-SLe
    Li T; Guo L; Li J; Mu X; Liu L; Song S; Luo N; Zhang Q; Zheng B; Jin G
    Int J Nanomedicine; 2024; 19():1249-1272. PubMed ID: 38348177
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tumour targetable and microenvironment-responsive nanoparticles simultaneously disrupt the PD-1/PD-L1 pathway and MAPK/ERK/JNK pathway for efficient treatment of colorectal cancer.
    Li Y; Qi M; Ding F; Lv Y; Ma J; Zhu Y
    J Drug Target; 2021 Apr; 29(4):454-465. PubMed ID: 33233956
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combination of tanshinone IIA and astragaloside IV attenuate atherosclerotic plaque vulnerability in ApoE(-/-) mice by activating PI3K/AKT signaling and suppressing TRL4/NF-κB signaling.
    Wang N; Zhang X; Ma Z; Niu J; Ma S; Wenjie W; Chen J
    Biomed Pharmacother; 2020 Mar; 123():109729. PubMed ID: 31887543
    [TBL] [Abstract][Full Text] [Related]  

  • 13. T cell-mediated targeted delivery of tadalafil regulates immunosuppression and polyamine metabolism to overcome immune checkpoint blockade resistance in hepatocellular carcinoma.
    Wang X; Zhang Q; Zhou J; Xiao Z; Liu J; Deng S; Hong X; Huang W; Cai M; Guo Y; Huang J; Wang Y; Lin L; Zhu K
    J Immunother Cancer; 2023 Feb; 11(2):. PubMed ID: 36813307
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Thermodynamic stability of cisplatin-loaded polymeric micelles and the phenotypic switching of the tumor-associated macrophages induced by combination of cisplatin-loaded micelles and Anti-PD-L1 antibody.
    Yuan H; Xue Y; Guo C; Song J; Zhang Y; Yin T; He H; Gou J; Tang X
    Int J Pharm; 2022 Jun; 622():121860. PubMed ID: 35654378
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Astragaloside IV inhibits the invasion and metastasis of SiHa cervical cancer cells via the TGF‑β1‑mediated PI3K and MAPK pathways.
    Zhang L; Zhou J; Qin X; Huang H; Nie C
    Oncol Rep; 2019 May; 41(5):2975-2986. PubMed ID: 30896841
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Quantitative proteomics analysis of differentially expressed proteins induced by astragaloside IV in cervical cancer cell invasion.
    Xia C; He Z; Cai Y
    Cell Mol Biol Lett; 2020; 25():25. PubMed ID: 32265995
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PD-L1 targeting high-affinity NK (t-haNK) cells induce direct antitumor effects and target suppressive MDSC populations.
    Fabian KP; Padget MR; Donahue RN; Solocinski K; Robbins Y; Allen CT; Lee JH; Rabizadeh S; Soon-Shiong P; Schlom J; Hodge JW
    J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32439799
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chronic Psychological Stress Attenuates the Efficacy of anti-PD-L1 Immunotherapy for Bladder Cancer in Immunocompetent Mice.
    Zhou Q; Qian Z; Ding W; Jiang G; Sun C; Xu K
    Cancer Invest; 2021; 39(6-7):571-581. PubMed ID: 34148483
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chemosensitive effects of Astragaloside IV in osteosarcoma cells via induction of apoptosis and regulation of caspase-dependent Fas/FasL signaling.
    Hu T; Fei Z; Wei N
    Pharmacol Rep; 2017 Dec; 69(6):1159-1164. PubMed ID: 29128795
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The combination of oxaliplatin and anti-PD-1 inhibitor promotes immune cells infiltration and enhances anti-tumor effect of PD-1 blockade in bladder cancer.
    Zhao Z; Liu S; Sun R; Zhu W; Zhang Y; Liu T; Li T; Jiang N; Guo H; Yang R
    Front Immunol; 2023; 14():1085476. PubMed ID: 36960067
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.